to adverse health outcomes including ischemic arterial disease (IAD). Whether estrogen receptor alpha 46 (ESR1) and beta (ESR2) polymorphisms modulate the effects of estradiol on IAD has not been 47 investigated. 48
Methods: In the Three-City prospective cohort study among subjects over 65 years, we used a case-49 cohort design in which plasma levels of 17β-estradiol were measured. After exclusion of 50 postmenopausal women using hormone therapy, a random subcohort of 533 women and 105 incident 51 cases of first IAD events over 4-year of follow-up were analyzed. Five common polymorphisms of 52 ESR1 and ESR2 were genotyped. Hazard ratios (HRs) of IAD for 1-standard deviation increase in 53 estradiol levels by genotypes were estimated from Cox models after adjustment for cardiovascular risk 54 factors and correction for multiple testing. We also investigated the role of haemostatis and 55 inflammation as potential mediators. 56
Results: Neither estradiol nor IAD risk were significantly associated with estrogen receptor 57 polymorphisms. Overall, IAD risk increased with estradiol (HR:1.40, 95%CI:1.11-1.77). Stratified 58 analysis by genotypes showed that estradiol was positively related to IAD risk in women with ESR1 59 rs9340799-AA genotype but not in women with AG/GG genotype (HR:1.62, 95%CI:1.22-2.17 and 60 HR:1.03, 95%CI:0.81-1.30, respectively; p for interaction<0.05). Additional adjustment for 61 haemostatic variables reduced the HR by about one third in women carrying rs9340799-AA genotype 62 (HR:1.41, 95%CI:1.06-1.90). 63
Conclusion: ESR1 rs9340799 genotype may modify IAD risk related to high endogenous estradiol 64 levels in older postmenopausal women. Hypercoagulability may act as a mediator. Few epidemiologic studies have been conducted to assess the association between circulating 69 levels of endogenous estradiol and the risk of chronic diseases in postmenopausal women (1). Despite 70 an important estrogen deficiency in postmenopausal women, high plasma estradiol levels have been 71 related to several adverse health outcomes including breast cancer (2), dementia (3), frailty (4) and all-72 cause mortality (5). In addition, previous data reported a positive relation of endogenous estrogens 73 with coronary heart disease (CHD) (6, 7) and stroke (8) but these associations were not independent of 74 traditional cardiovascular risk factors such as diabetes and body mass index (BMI). In a recent study, 75 we found that high plasma level of endogenous estradiol was an independent predictor of ischemic 76 arterial disease (IAD) in older postmenopausal women (9). 77
Estrogens exert their actions via two distinct types of estrogen receptors (ER): ER-α and ER-β, 78 encoded by the estrogen receptor α gene (ESR1) located on chromosome 6 and the estrogen receptor β 79 gene (ESR2) located on chromosome 14, respectively. ERs are expressed in many tissues especially in 80 vascular endothelial and smooth muscle cells of cerebral and coronary arteries and may play a role in 81 the development of cardiovascular disease (10, 11) . Previous studies suggested that the rs2234693 and 82 rs9340799 single nucleotide polymorphism might influence the expression of ESR1 (12) and affect the 83 function of estrogen on arterial disease including CHD and stroke (13, 14) . However, a recent meta-84 analysis concluded to a lack of association between ESR1 polymorphisms and CHD (15). Conflicting 85 results about the association of ESR1 polymorphisms with the risk of stroke have been also reported 86 (16, 17) . Similarly, data on association of ESR2 polymorphisms (including rs1256049 and rs1271572) 87 with the risk of CHD or stroke have not been consistent (18, 19) . 88
Despite the potential role of estrogens and their receptors in the development of IAD, no study 89 has evaluated whether ER polymorphisms could modulate the effects of estradiol on IAD. Therefore, 90
we investigated the risk of CHD and ischemic stroke related to plasma estradiol levels by ESR1 and 91
ESR2 polymorphisms in a cohort study among postmenopausal women over 65 years, who did not use 92 hormone therapy. In addition, since estradiol is known to be associated with haemostatic and inflammation parameters (20, 21) , their role was evaluated as potential mediators in the association of 94 both estradiol and ER polymorphisms with IAD risk. 95
METHODS 97 98
Population study 99 100
The Three-City (3C) study is a large ongoing French prospective cohort designed to evaluate 101 the risk of dementia, CHD and stroke, in subjects over 65 years. The study was approved by the Ethics 102
Committee of the University Hospital of Kremlin-Bicêtre and a written informed consent was obtained 103 for all participants. A detailed methodology of the study has been previously described (22 smoking status and consumption of alcohol were systematically collected at baseline. Women were 114 classified as current hormone therapy users if they used hormone therapy at any time during the 3 115 months before the inclusion. BMI was calculated as weight in kilograms divided by height in meters 116 squared. Hypertension status was defined as a high blood pressure measurement (systolic blood 117 pressure ≥140mmHg and/or diastolic blood pressure ≥90mm Hg) or antihypertensive treatment at 118 inclusion. Participants were categorized as diabetic if their fasting blood glucose level exceeded 119 1.26g/L (or 7mmol/L) or if they used current treatment for diabetes at baseline. Hypercholesterolemia 120 was considered present if the fasting blood total cholesterol level was above 2.40g/L or if the subjects were treated for hypercholesterolemia. Smoking status was studied in three categories (never, past and 122 current). 123 124 Follow-up and event ascertainment 125 126 Every 2 years after inclusion, the participants have been reexamined for the detection of 127 dementia and IAD events. For this study, we focused on data collected over the 4-year follow-up. IAD 128 consisted of either CHD or ischemic stroke during the follow-up. These events were adjudicated 129 within an independent group of experts using medical documentation. CHD was defined as a 130 hospitalization for either stable or unstable angina pectoris, coronary dilatation, artery by-pass, 131 myocardial infarction, or CHD death. Non-fatal CHD were ascertained using hospital charts and 132 practitioners' reports. CHD deaths were validated by reviewing hospital records, medical data 133 obtained from family physicians or specialists and proxy interviews (coded I210 to 219, I251 to 259, 134 I461 and R960 according to 10th version of the International Classification Disease) as described (23). 135
Stroke events were defined as a rapid onset of a neurological deficit lasting more than 24 hours and 136 confirmed by a lesion compatible with an acute stroke on computed tomography or magnetic 137 resonance imaging of the brain. Ischemic or hemorrhagic stroke events were classified by a review of 138 brain imaging. Our study focused on IAD and hemorrhagic stroke events were therefore excluded. For 139 subjects who presented with both CHD and ischemic stroke during follow-up, we used the first 140 cardiovascular event that occurred. 141
Case-cohort study 142 143
A case-cohort study was designed from the 3C study to investigate the association of blood 144 biomarkers with cardiovascular risk and dementia (24). The case-cohort study design was described 145 firstly by Prentice (25) and consists of a random sample of the original cohort together with all 146 incidents cases of this cohort. In practice, after exclusion of men (n=1,264), current users of hormone 147 therapy (n=120), women with a personal history of CHD or stroke at baseline (n=86) and lost for follow-up (n=16), the subcohort included 537 women (522 non-cases and 15 cases) to which 91 149 incident cases of IAD outside the subcohort were added. The detailed flowchart has been described 150 (9). Data on all ER polymorphisms were missing for 5 subjects. The final sample therefore consisted 151 of 623 women, 518 non-cases and 105 incident cases of a first IAD event including 67 CHD and 38 152 ischemic strokes. 153 154
Blood collection and laboratory methods 155 156
At baseline, blood samples were collected for more than 90% of the full cohort. Plasma 157 samples were available for all the subjects included in the case-cohort study. EDTA plasmas were 158 obtained after one centrifugation at 3,000g and immediately stored at -80°C in 1-mL plastic tubes. 159
Plasma total estradiol was measured with a sensitive direct radioimmunoassay (RIA) using an 160
Orion Diagnostica device (Spectria, Espoo, Finland). The minimum detectable concentration was 161 2pg/mL (7.3pmol/L). The intraassay and interassay coefficient of variation (CV) were 17.6% and 162 18.1% respectively, for total estradiol concentrations of 3.2pg/mL (12pmol/L) and were 2.8% and 163 5.8% respectively, for total estradiol concentrations of 24pg/mL (88pmol/L). 164 DNA was extracted from white blood cells (Puregene Kit, Qiagen, France) and stored at-80°C. 165
Genotyping of ER polymorphisms was performed by Kbiosciences (Hoddesdon Herts, UK) using their 166 competitive allele specific polymerase chain reaction (PCR) single-nucleotide polymorphism (SNP) 167 genotyping system (KASPar). Fluorescence scanning in a BMG Labtech Pherastar scanner analyzed 168 the amplified PCR products and the results were interpreted with KlusterCaller 1.1 software. The error 169 rate for the KASPar assay system is less than 0.3%. The two most commonly studied ESR1 170 polymorphisms were investigated: rs2234693 and rs9340799 (otherwise known as PvuII and XbaI), 171
which are located at position 397 and 351 of intron 1, respectively. Three ESR2 polymorphisms were 172 genotyped: rs1256049 (otherwise known as RsaI), rs4986938 (otherwise known as AluI) and 173 rs1271572, which are located in position 1082 of exon 5, in position 1730 of the 3'-untranslated region 174 of exon 8 and in the promoter region, respectively. The selection of these polymorphisms was based on previously published associations with risk of CHD and stroke (15, 17, 18) and possible functional 176 significance (12, 26, 27) . 177
Laboratory methods for haemostatic variables and CRP have been described (20, 24, 28, 29) . 178
Briefly, fibrinogen was measured in citrated plasmas by the kinetic method of Clauss and von 179
Willebrand factor and fibrin D-dimer by ELISAs. Thrombin generation was measured by the 180 calibrated automated thrombography. We used peak height (highest value of thrombin generated), and 181 endogenous thrombin potential (ETP; total quantity of thrombin generated) in our analyses. High-182 sensitivity serum C-reactive protein (hs-CRP) was measured using a particle-enhanced turbidimetric 183 immunoassay. The association of both estradiol levels and ER polymorphisms with IAD risk and their 203 interactions were investigated using weighted Cox proportional-hazards models adapted for the case-204 cohort design by the method of Barlow (31, 32) . Because age is sharply associated with IAD risk, age 205 as time-scale was used as recommended (33). The proportional hazards assumption was checked for 206 each model. Additive, dominant and recessive models were initially examined to determine which 207 genetic model best described the data. Therefore, results are presented assuming a genotype model in 208 dominant model with a 2-level categorical variable. The hazard ratios (HRs) and 95% confidence 209 intervals (95%CI) by ER genotypes were estimated for 1-standard deviation increase in the log-210 transformed estradiol distribution. Estradiol x ER genotypes interaction terms were introduced into 211 statistical models. The HRs for IAD were adjusted for study center and traditional cardiovascular risk 212 factors including BMI, diabetes, hypertension, hypercholesterolemia and smoking status. In addition, 213
given that five SNPs were investigated, Bonferroni correction for multiple comparisons was used. The 214
HRs for IAD were further adjusted for haemostatic and inflammation markers including fibrinogen, 215 thrombin generation, von Willebrand factor, fibrin D-dimer and hs-CRP, to evaluate the part of the 216 excess risk explained by these variables. Of note, data on haemostatic and inflammation variables 217 were missing for 25 subjects. 218
For each ER polymorphism, the risk of IAD was also investigated by tertiles of estradiol 219 distribution and the low tertile was chosen as the reference group. Tests for linear trend across the 3 220 categories of estradiol levels were used to investigate the significance of the variables, after having 221 evaluated the linearity of the associations. To assess the linearity of the relation of estradiol levels with 222 IAD risk, we used tests based on the difference in the log-likelihood between two models of prediction 223 (one with 2 dummy variables corresponding to the tertiles of the estradiol levels and the other 224
including the qualitative ordinal variable in 3 categories). All tests were non-significant and we did not 225 reject the hypothesis of linearity. 226
Finally, a separate analysis was performed for CHD and ischemic stroke, including the first 227 arterial event. Similarly to analyses on IAD risk, the HRs of CHD and ischemic stroke in relation to 228 estradiol levels were estimated by ER polymorphisms with a multivariate Cox model. 229
Statistical analyses were performed with the Statistical Analysis System software version 9.2 231 (SAS Institute Inc, Cary, NC). 232
RESULTS 234 235
Baseline characteristics are described for 533 women in the whole subcohort and according to 236 rs9340799 genotype (table 1). The distribution of ESR1 rs9340799 polymorphisms in the subcohort 237 was similar to those expected in Caucasian subjects, as follows: 45.6%, 42.9%, and 11.5% for AA, 238 AG and GG respectively. No significant difference was detected among traditional cardiovascular risk 239 factors between women with rs9340799-AA genotype and those with rs9340799-AG/GG genotype. 240
Mean levels of total estradiol were similar across rs9340799 genotypes. There was no significant 241 association between estradiol levels and other ER polymorphisms (data not shown). 242
243
The genotypic frequencies of ER polymorphisms were in agreement with the Hardy-244
Weinberg equilibrium. The two ESR1 polymorphisms were in strong linkage disequilibrium and so 245 were the three ESR2 polymorphisms (all D' ranged from 0.90 to 1.00). 246
247
No significant association was found between IAD risk and the different ER polymorphisms 248 (data not shown). After adjustment for traditional cardiovascular risk factors, plasma estradiol levels 249
were positively associated with IAD risk in the whole population sample (HR:1.40 for 1-SD log 250 estradiol change, 95%CI:1.11-1.77). Adjusted HR for IAD events and 95% CI in relation to estradiol 251 levels by ER polymorphisms are given in table 2 before and after Bonferroni correction. With regard 252 to ESR1 rs9340799 polymorphism, the risk of IAD was positively associated with total estradiol in 253 women with AA genotype but not in women with AG/GG genotype (HR:1.62, 95% CI:1.22-2.17 and 254 HR:1.03, 95%CI:0.81-1.30, respectively; p for interaction<0.05). In women with AA genotype, high 255 levels of estradiol increased significantly the risk of IAD compared to the lowest estradiol levels (HR: 256 3.78, 95%CI:1.59-8.99 for the higher tertile vs the lower tertile, p for linear trend<0.01). After 257
Bonferroni correction for multiple testing, the estradiol x rs9340799 genotype interaction remained 258 significant. Similar associations were observed for rs2234693 polymorphism, although the interaction 259 between estradiol levels and rs2234693 polymorphism was not significant. No significant interaction 260 was detected between estradiol levels and ER-β polymorphisms on IAD risk.
Estradiol was positively correlated to fibrinogen (r=0.21, p<0.01), peak height of thrombin 263 generation (r=0.10, p=0.13) and hs-CRP (r=0.38, p<0.01) in women with rs9340799-AA genotype. 264
After additional adjustment for haemostatic variables, the HR for IAD risk in women with AA 265 genotype (HR:1.58 for 1-SD log estradiol change, 95%CI:1.21-2.05) was reduced to 1.41 266 (95%CI:1.06-1.90), suggesting that hypercoagulability explained 29 % of the excess risk of IAD. 267
Adjustment for hs-CRP alone or combined with haemostatic variables made no substantial change to 268 the results (data not shown). 269
270
When the analyses were stratified by type of arterial events, total estradiol was positively 271 associated with CHD risk in women with rs9340799-AA genotype, but not in women with rs9340799-272 AG/GG genotype (adjusted and corrected HR: 1.93, 95% CI: 1.28-2.91 and HR: 1.01, 95% CI: 0.76-273 1.35, respectively; p for interaction<0.05). No significant interaction was found between rs9340799 274 genotype and estradiol for the risk of ischemic stroke. In this prospective study, neither estradiol levels nor IAD risk were significantly associated 280 with ER polymorphisms in older postmenopausal women. However, we found that genetic variations 281 in ESR1 modified the risk of IAD related to high endogenous estradiol levels. Plasma estradiol levels 282
were positively associated with IAD risk in women carrying rs9340799-AA genotype but not in 283 women carrying rs9340799-AG/GG genotype. The excess risk of IAD in women with AA genotype 284 was partially explained by hypercoagulability. No interaction between estradiol levels and other ER 285 polymorphisms was observed in relation with the risk of IAD. 286
287
Many studies have investigated the association of ER polymorphisms with the risk of IAD but 288 previous data led to conflicting results. The reasons for such discrepancies include differences in study 289 population, design and analysis, together with a strong heterogeneity in quality of investigations (15). 290 Importantly, while the effect of ER polymorphisms on IAD may be different for women and men, few 291 data were stratified by sex. Furthermore, use of hormone therapy and/or menopause status were not 292 taken into account in most studies among women and ultimately, only few studies focused on 293 postmenopausal women. A population-based prospective cohort study including 3,488 older 294 postmenopausal women showed a positive association of ESR1 rs2234693-T/rs9340799-A haplotype 295 with the risk of myocardial infarction (34). However, although the results were adjusted for use of 296 hormone therapy, no data were given among women not using estrogens. Consistently, another study 297 excluding women using hormone therapy, reported an increased risk of stroke in women carrying 298 ESR1 rs2234693-TT (17). By contrast, a Japanese case-control study including highly selected 299 postmenopausal women reported that the ESR1 rs2234693-CC and rs9340799-GG genotypes were 300 more common in women with coronary artery disease than in controls (35).With regard to ESR2 301 polymorphisms, the Women's Health Study showed that rs1256049-G and rs1271572-T alleles 302 increased CHD risk but not stroke risk, whereas rs4986938 polymorphism was associated with neither 303 CHD nor stroke (18). Most other investigations among postmenopausal women failed to detect an 304 association of either CHD or stroke risk with ESR1 and ESR2 polymorphisms (16, 19, (36) (37) (38) .
Therefore, our data are consistent with these null findings which are also supported by a meta-analysis 306 (15). 307 308 Few studies investigated the interaction between estradiol and ER polymorphisms in relation 309 to health outcomes in postmenopausal women. Interestingly, a dutch case-cohort study showed that 310 the positive association between estradiol and breast cancer risk was more pronounced among women 311 with rs2234693-CT/ TT genotype than among those with rs2234693-CC genotype (39). This result 312 may be relevant to our finding because both rs2234693 and rs9340799 are in linkage disequilibrium. 313
To our knowledge, the 3C study is the first to show that ESR1 polymorphisms may modulate the 314 association between plasma estradiol levels and IAD risk. As previously described, plasma estradiol 315 levels were positively associated with IAD risk in the whole population irrespective of ER genotypes 316 (9). Adjustment for traditional cardiovascular risk factors yielded similar results suggesting no major 317 mediator role of obesity, diabetes, hypercholesterolemia, hypertension and smoking status. Therefore, 318
we can hypothesize that the relation between estradiol an IAD risk among women with rs9340799-AA 319 genotype could be driven by other mechanisms involved in atherothrombosis such as inflammation 320 and hypercoagulability. Both estradiol levels and IAD risk are known to be positively associated with 321 CRP in postmenopausal women (21, 29, 40) . Moreover, one study reported that the rs2234693-T allele 322 carriers exhibited an enhanced inflammatory response compared to the CC homozygotous (41). Of 323 note, while rs2234693 and rs9340799 polymorphisms are in linkage disequilibrium, inflammation 324 could be similarly increased in women with rs9340799-AA genotype as those with rs2234693-TT 325 genotype. Nevertheless, in our study, the additional adjustment for hs-CRP did not change the results, 326
suggesting that the inflammation did not explain the excess of IAD risk. Alternatively, given that high 327 estradiol levels and IAD risk are known to be associated with hypercoagulability (20, 24, 28, 42) , the 328 association between estradiol and IAD risk could also be mediated through haemostatic variables. 329
Interestingly, a nested case-control study in the Women's Health Initiative trials reported an increased 330 response of plasmin-antiplasmin to hormone therapy in women with rs9340799-AA genotype 331 compared to women with rs9340799-AG or rs9340799-GG genotypes(38). Although exogenous and 332 endogenous estrogens might have different metabolic and vascular effects, it can be suggested that high endogenous estradiol levels play a role in the thrombotic component of IAD through blood 334 coagulation and fibrinolysis activation. In our study, hypercoagulability explained a part of the relation 335 between estradiol and IAD risk in women with rs9340799-AA genotype. Further adjustment for hs-336 CRP did not change the results, suggesting that changes in coagulation pathway play a more important 337 role in the development of IAD than inflammation. Other unmeasured haemostatic variables could 338 also be involved in the association of IAD risk with estradiol in women with rs9340799-AA genotype 339 and further data on clotting factors are required. 340
Increased IAD risk in women with elevated estradiol levels and carrying rs9340799-AA 341 genotype does not necessarily imply that relationship is causal. First, our findings could be due to the 342 chance. Second, studied genetic variants may be highly correlated with other variants within ESR1 or 343 nearby genes that are themselves "causal" in the development of IAD, suggesting that the ER 344 polymorphisms are not the only factor that determines the effect of estrogen on IAD. Few studies 345 support the functional importance of ESR1 polymorphisms altering the quantity or the quality of ER-α 346 transcripts or resulting proteins and the underlying mechanisms related to a direct effect of ER 347 polymorphism in vascular biology remain to be clarified (12, 27, 43) . 348
349
The strengths of our study include the prospective population-based and multicenter cohort 350 design with a high participation rate during the 4 years of follow-up. Moreover, baseline data were 351 collected by a direct interview and high-quality methods of ascertainment of cardiovascular risk 352 factors and disease outcome were used. In addition, estradiol measurements and genotyping were 353 conducted without knowledge of the case or non-case status, using validated methodology. 354
Furthermore, our genetic-association study cannot be influenced by stratification population or 355 heterogeneity because most participants were Caucasian. 356
357
Our study has several limitations. Firstly, the small number of incident cases may result in a 358 lack of statistical power, especially for subgroup analyses by CHD or stroke event. In addition, 359 multiple comparisons by different polymorphisms could result in falsely positive findings. However, 360 our results remained significant after Bonferroni correction for multiple testing. Secondly, our population study included older women who were aged 73 years on average and mostly Caucasian. 362
Our data cannot therefore be generalized to younger postmenopausal women or other ethnics. With 363 regard to the sex steroid hormones assays, especially at low levels of estradiol in postmenopausal 364 women, conventional RIAs with preceding purification steps would provide more reliable and 365 accurate measurements of plasma estradiol as compared with direct RIA (44). However, measurement 366 error related to direct RIA would bias our analysis toward the null hypothesis, resulting in a potential 367 underestimation of the true associations (1). On the other hand, the blood concentration of estrogens 368 does not necessarily reflect the biologically active forms at the tissue level, as they are dependent on 369 the local enzyme activity and the binding on the protein transporters such as sex hormone binding 370 globulin. 371 372 373
In conclusion, ESR1 rs9340799-AA genotype may increase IAD risk related to high 374 endogenous estradiol levels in older postmenopausal women and hypercoagulability may explain a 375 part of this excess of risk. These innovative results have the potential to improve the stratification of 376 IAD risk in postmenopausal women whose IAD risk may depend upon both plasma estradiol levels 377
and ESR1 genotype and their interaction. However, further investigations with larger sample size are 378 needed to replicate these findings and to assess the interaction between estradiol levels and ESR1 379 genetics polymorphism on CHD and stroke risk separately. 380
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